A recently approved multiple sclerosis drug was voluntarily pulled from the market on Monday, following reports of a death and illness related to the treatment. NPR's Madeleine Brand speaks with NPR's Joanne Silberner about the affects the withdrawal may have on the FDA.
Copyright 2005 NPR
